A critical role for miR-184 in the fate determination of oligodendrocytes.
BCL2L1
LINGO1
NPCs
Oligodendrocytes
SOX1
miR-184
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
29 03 2019
29 03 2019
Historique:
received:
17
09
2018
accepted:
06
03
2019
revised:
14
01
2019
entrez:
30
3
2019
pubmed:
30
3
2019
medline:
26
6
2020
Statut:
epublish
Résumé
New insights on cellular and molecular aspects of both oligodendrocyte (OL) differentiation and myelin synthesis pathways are potential avenues for developing a cell-based therapy for demyelinating disorders comprising multiple sclerosis. MicroRNAs (miRNA) have broad implications in all aspects of cell biology including OL differentiation. MiR-184 has been identified as one of the most highly enriched miRNAs in oligodendrocyte progenitor cells (OPCs). However, the exact molecular mechanism of miR-184 in OL differentiation is yet to be elucidated. Based on immunochemistry assays, qRT-PCR, and western blotting findings, we hypothesized that overexpression of miR-184 in either neural progenitor cells (NPCs) or embryonic mouse cortex stimulated the differentiation of OL lineage efficiently through regulating crucial developmental genes. Luciferase assays demonstrated that miR-184 directly represses positive regulators of neural and astrocyte differentiation, i.e., SOX1 and BCL2L1, respectively, including the negative regulator of myelination, LINGO1. Moreover, blocking the function of miR-184 reduced the number of committed cells to an OL lineage. Our data highlighted that miR-184 could promote OL differentiation even in the absence of exogenous growth factors and propose a novel strategy to improve the efficacy of OL differentiation, with potential applications in cell therapy for neurodegenerative diseases.
Sections du résumé
BACKGROUND
New insights on cellular and molecular aspects of both oligodendrocyte (OL) differentiation and myelin synthesis pathways are potential avenues for developing a cell-based therapy for demyelinating disorders comprising multiple sclerosis. MicroRNAs (miRNA) have broad implications in all aspects of cell biology including OL differentiation. MiR-184 has been identified as one of the most highly enriched miRNAs in oligodendrocyte progenitor cells (OPCs). However, the exact molecular mechanism of miR-184 in OL differentiation is yet to be elucidated.
METHODS AND RESULTS
Based on immunochemistry assays, qRT-PCR, and western blotting findings, we hypothesized that overexpression of miR-184 in either neural progenitor cells (NPCs) or embryonic mouse cortex stimulated the differentiation of OL lineage efficiently through regulating crucial developmental genes. Luciferase assays demonstrated that miR-184 directly represses positive regulators of neural and astrocyte differentiation, i.e., SOX1 and BCL2L1, respectively, including the negative regulator of myelination, LINGO1. Moreover, blocking the function of miR-184 reduced the number of committed cells to an OL lineage.
CONCLUSIONS
Our data highlighted that miR-184 could promote OL differentiation even in the absence of exogenous growth factors and propose a novel strategy to improve the efficacy of OL differentiation, with potential applications in cell therapy for neurodegenerative diseases.
Identifiants
pubmed: 30922384
doi: 10.1186/s13287-019-1208-y
pii: 10.1186/s13287-019-1208-y
pmc: PMC6440085
doi:
Substances chimiques
MIRN184 microRNA, human
0
MIRN184 microRNA, mouse
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Références
J Vis Exp. 2012 Dec 20;(70):
pubmed: 23288248
Stem Cells Transl Med. 2016 Nov;5(11):1550-1561
pubmed: 27400790
J Biol Chem. 2012 Jun 22;287(26):22184-95
pubmed: 22514275
Development. 2010 Jul;137(13):2127-32
pubmed: 20504959
Nat Rev Neurosci. 2015 Dec;16(12):756-67
pubmed: 26585800
Stem Cells Dev. 2013 Sep 15;22(18):2459-76
pubmed: 23621561
Nat Med. 2007 Oct;13(10):1228-33
pubmed: 17906634
Front Neuroanat. 2009 Jun 01;3:5
pubmed: 19521542
Neuron. 2010 Mar 11;65(5):612-26
pubmed: 20223198
Cell J. 2017 Apr-Jun;19(1):1-10
pubmed: 28367411
Neurotoxicology. 2015 Dec;51:87-95
pubmed: 26254736
Cold Spring Harb Perspect Biol. 2015 Aug 20;8(2):a020453
pubmed: 26492571
Stem Cell Reports. 2014 Aug 12;3(2):250-9
pubmed: 25254339
Development. 2011 Oct;138(20):4443-50
pubmed: 21880787
Dev Biol. 2011 Feb 15;350(2):429-40
pubmed: 21147085
Nat Neurosci. 2003 Nov;6(11):1162-8
pubmed: 14517545
Stem Cells Dev. 2011 Mar;20(3):503-14
pubmed: 20632795
Dev Biol. 2004 May 15;269(2):580-94
pubmed: 15110721
Nat Rev Neurosci. 2007 Jun;8(6):427-37
pubmed: 17514196
Acta Neuropathol. 2012 May;123(5):627-38
pubmed: 22327362
Mol Cell Neurosci. 2014 May;60:36-42
pubmed: 24583087
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17468-73
pubmed: 24101522
Mol Biol Cell. 2012 Aug;23(15):2867-78
pubmed: 22696677
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1114-20
pubmed: 19723505
Nat Rev Neurosci. 2008 Nov;9(11):839-55
pubmed: 18931697
Nat Rev Neurosci. 2005 Sep;6(9):683-90
pubmed: 16136172
Science. 1999 Jul 30;285(5428):754-6
pubmed: 10427001
Nature. 2001 Nov 1;414(6859):112-7
pubmed: 11689956
J Med Genet. 2016 Jan;53(1):24-33
pubmed: 26510428
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Stem Cell Res Ther. 2017 May 11;8(1):110
pubmed: 28494789
Ann Neurol. 2013 Sep;74(3):317-27
pubmed: 23955638
Curr Opin Neurol. 2008 Oct;21(5):607-14
pubmed: 18769257
EMBO J. 2002 Dec 2;21(23):6452-60
pubmed: 12456652
Dev Cell. 2013 Jun 24;25(6):549-50
pubmed: 23806613
Nature. 2012 Jul 26;487(7408):443-8
pubmed: 22801498
PLoS One. 2010 May 05;5(5):e10480
pubmed: 20463920
Nat Rev Neurosci. 2010 Jun;11(6):377-88
pubmed: 20485363
Neurosci Res. 2005 Apr;51(4):331-6
pubmed: 15740796